Tyker, Albina
Ventura, Iazsmin Bauer
Lee, Cathryn T.
Strykowski, Rachel
Garcia, Nicole
Guzy, Robert
Jablonski, Renea
Vij, Rekha
Strek, Mary E.
Chung, Jonathan H.
Adegunsoye, Ayodeji
Funding for this research was provided by:
Boehringer Ingelheim
Galapagos
FibroGen
Genentech
Article History
Received: 20 August 2021
Accepted: 9 November 2021
First Online: 24 November 2021
Competing interests
: MES has received institutional support to conduct ILD clinical trials for Boehringer Ingelheim and Galapagos, fees for clinical trial adjudication committee service from Fibrogen and editorial support from Boehringer Ingelheim. JHC has received speaking and advisory board fees from Genentech and Boehringer Ingelheim AA has received speaking and advisory board fees from Genentech and Boehringer Ingelheim and is supported by a career development award from the National Heart, Lung, and Blood Institute (NHLBI K23HL146942). All other authors (AT, IBV, CTL, RS, NG, RG, RJ, RV) have no competing interests to disclose.